Publication Type:

Journal Article

Source:

National Journal of Physiology, Pharmacy and Pharmacology, Mr Bhawani Singh, Volume 7, Number 12, p.1444-1446 (2017)

URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037036484&doi=10.5455%2fnjppp.2017.7.0724615072017&partnerID=40&md5=d419394f690b6e58fd90d44334ca560e

Keywords:

adult, antibiotic agent, BCR ABL protein, bone marrow biopsy, bone pain, case report, chronic myeloid leukemia, clinical article, Dasatinib, drug dose increase, drug response, female, fever, human, human tissue, hydroxyurea, hyperplasia, imatinib, limb pain, megakaryocytic hyperplasia, middle aged, mutation rate, neutropenia, protein tyrosine kinase inhibitor, reverse transcription polymerase chain reaction, review, Sanger sequencing, thrombocyte count, thrombocytosis

Abstract:

<p>This report aims to assess the viability of various challenging approaches such as tyrosine kinase inhibitors (TKIs) therapy, chemotherapy, and stem cell transplantation in patients with chronic myeloid leukemia (CML), especially for those in an advanced phase. Although standard treatments have been extremely effective in combating CML propagation and negating the disease symptoms along with an increased survival rate, these traditional treatment methods have experienced an increased failure rate due to TKI treatment resistance. A common mechanism that can be attributed to the increase in TKI resistance is the increasing mutations of the BCR-ABL 1 kinase domain. These mutations can be clearly observed in clinical trials. Currently, there are five BCR-ABL 1 kinase inhibitors that are approved for the safe treatment of CML. These are imatinib, dasatinib, nilotinib, bosutinib, and ponatinib. Mutational testing should be carried out on patients in such cases that show little response to traditional TKI therapy.In this report, we evaluate a patient who has been diagnosed with an accelerated phase CML and requires constant monitoring to tailor the treatment program to their requirements. © 2017 Dawnwin Joseph, et al.</p>

Notes:

cited By 0

Cite this Research Publication

D. Joseph, Varghese, D. R., Prabhu, R., and Anila, K. N., “Mechanism of resistance to tyrosine kinase inhibitors - A case report and review”, National Journal of Physiology, Pharmacy and Pharmacology, vol. 7, pp. 1444-1446, 2017.

207
PROGRAMS
OFFERED
6
AMRITA
CAMPUSES
15
CONSTITUENT
SCHOOLS
A
GRADE BY
NAAC, MHRD
8th
RANK(INDIA):
NIRF 2018
150+
INTERNATIONAL
PARTNERS
  • Amrita on Social Media

  • Contact us

    Amrita Vishwa Vidyapeetham
    Amritanagar, Coimbatore - 641 112
    Tamilnadu, India
    • Fax: +91-422-2686274
    • Coimbatore : +91 (422) 2685000
    • Amritapuri   : +91 (476) 280 1280
    • Bengaluru    : +91 (080) 251 83700
    • Kochi              : +91 (484) 280 1234
    • Mysuru          : +91 (821) 234 3479
    • Contact Details »